Status:
COMPLETED
A Sub Study of the Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Miricorilant in Patients With Presumed Nonalcoholic Steatohepatitis (NASH)
Lead Sponsor:
Corcept Therapeutics
Conditions:
Nonalcoholic Steatohepatitis (NASH)
Eligibility:
All Genders
18-75 years
Brief Summary
This optional sub study is a part of the phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH)
Detailed Description
This optional sub study is a part of the phase 1b, Open-Label Study is to assess the safety, efficacy of miricorilant in patients with presumed Nonalcoholic Steatohepatitis (NASH). All patients who p...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Have participated in either Study CORT118335-861 (current study) or Study CORT118335-860 (Corcept Phase 2a NASH study) and received at least one dose of miricorilant; this includes patients who terminated early from the study or completed the study.
- Have not participated in any other clinical trial following study completion in either Study CORT118335-861 or Study CORT118335-860.
Exclusion
Key Trial Info
Start Date :
March 4 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 18 2023
Estimated Enrollment :
22 Patients enrolled
Trial Details
Trial ID
NCT05320146
Start Date
March 4 2022
End Date
July 18 2023
Last Update
August 19 2024
Active Locations (9)
Enter a location and click search to find clinical trials sorted by distance.
1
Site 207
Chandler, Arizona, United States, 85224
2
Site 209
Tucson, Arizona, United States, 85712
3
Site 214
Panorama City, California, United States, 91402
4
Site 233
Santa Ana, California, United States, 92704